玻璃酸钠联合复方倍他米松治疗膝骨关节炎的疗效观察

摘要

Objective To analyze the curative effect of sodium hyaluronate combined with compound betamethasone in the treatment of knee osteoarthritis (KOA).Methods A total of 420 outpatients with knee osteoarthritis admitted and treated in Shandong Provincial Qianfoshan Hospital from May 2016 to March 2017 were divided into control group and experimental group by the random number table method.The control group was given weekly intra-articular injection of sodium hyaluronate injection 2 ml for 5 weeks,and the experimental group was given compound betamethasone injection 1 ml at the I st week and 3rd week on the basis of the control group.Curative effect was evaluated by the WOMAC score and VAS score in the two group 1 week,3 weeks,5 weeks after treatment and 1 week,3 weeks,5 weeks after withdrawal.Results The WOMAC score and VAS score of the experimental group were obviously lower than those of the control group,with statistically significant differences (P＜0.05);there were no statistically significant differences in WOMAC score and VAS score between the two groups 1 week,3 weeks,5 weeks after withdrawal (P＞0.05).Conclusion The effect of the combination of sodium hyaluronate and compound betamethasone is faster than that of sodium hyaluronate,but the curative effect is transitory.%目的 分析玻璃酸钠联合倍他米松对膝骨关节炎(KOA)的疗效.方法 以千佛山医院2016年5月至2017年3月期间门诊随访诊治的KOA患者420例作为研究对象,将420患者分为对照组和实验组.对照组膝关节内注射玻璃酸钠注射液2 ml,每周注射1次,连用5周.实验组膝关节内注射玻璃酸钠注射液2 ml,每周注射1次,连用5周,并在第1周、第3周注射复方倍他米松注射液1 ml.两组患者在治疗期间及停药随访期间的WOMAC评分及VAS评分作为评价治疗效果的标准.结果 在治疗后1、3、5周,观察组的WOMAC评分、VAS评分明显低于对照组,差异有统计学意义(P＜0.05);但在停药后1、3、5周,两组的WOMAC评分、VAS评分比较差异无统计学意义(P＞0.05).结论 玻璃酸钠联合复方倍他米松比单纯注射玻璃酸钠治疗膝骨关节炎起效快,但作用效果短暂.